Hone Health gives readers more product detail than many general menopause services: its Premium information lists an oral progesterone capsule as compounded. Yet the central question is still why that medicine would be proposed. A recognizable route and a price cannot explain the relationship between a treatment goal, a person’s history and another hormone already in use.
We reviewed Hone’s service, Premium membership and capsule-benefit pages on September 29, 2026. This assessment separates the documented offer from the evidence needed for an individual plan. In particular, a broad cancer-prevention claim should not be mistaken for proof that this compounded capsule prevents cancer or is appropriate for every estrogen user.
The capsule is named, but the clinical purpose is not personal
The Premium medication menu identifies a compounded oral progesterone capsule and separately lists a cream. That establishes what the provider advertises, not a prescription for the reader or equivalence between the forms. The menopause service page describes several possible treatment goals. Before those descriptions become a plan, the clinician would need to explain what the capsule is intended to do in this particular context. The systemic estrogen guide distinguishes an endometrial-protection rationale from a general symptom discussion. Neither an online menu nor the presence of estrogen on a medicine list completes that assessment.
Cancer prevention needs a much narrower explanation
Hone’s capsule-benefit page includes cancer-prevention wording without establishing a defined cancer outcome for the listed compounded product. The FDA label for Prometrium is a useful contrast in precision: its endometrial-hyperplasia indication concerns nonhysterectomized postmenopausal women receiving conjugated estrogen tablets. Hyperplasia prevention in that specified setting is not a general claim to prevent cancers. The label belongs to that named approved product, not Hone’s compound. Renew Youth’s review considers other broad progesterone claims. Comparing the wording helps identify a question for the clinician; it does not transfer an approved product’s evidence to a different formulation.
A compounded preparation has its own evidence boundary
The FDA describes compounded drugs as lacking FDA approval and agency review for safety, effectiveness and quality before marketing. That distinction matters because Hone expressly uses compounded language in its capsule listing. A shared hormone name does not establish that an ingredient list, absorption finding or indication from another product applies unchanged. Nor does the listing identify a manufacturer, a complete excipient declaration or an individual dispensing arrangement. The meaningful question is how the selected preparation supports the proposed purpose and what alternatives or limitations the clinician discusses. This review cannot decide that question from a benefit list or certify the contents of a supplied capsule.
History includes the reason for an operation
The uterus question is not answered adequately by a yes-or-no marketing category. In its 2026 endometriosis guidance, the British Menopause Society discusses circumstances after hysterectomy in which combined treatment may be considered, with residual disease and individual risks affecting the decision. The document acknowledges limited high-quality evidence rather than offering a universal rule. This is UK professional context, not proof of Hone’s practice or a recommendation to add medicine. The hysterectomy history guide helps frame what needs clarification. Hone’s public offer does not demonstrate a particular surgical-record review or establish how a given past diagnosis would change its clinician’s advice.
The membership and medicine amounts cannot be collapsed
Hone’s Premium description gives a $65 initial at-lab testing fee and a $155 monthly membership, with medication charged separately. It lists the compounded progesterone capsule at an estimated $49 per month and the cream at $79; medicine prices may vary and exclude initial testing and membership. Follow-up consultations and laboratory work are described as included in Premium, with cancellation taking effect at the period’s end. These units do not turn the capsule estimate into a complete care price. Lifeforce has a different, internally inconsistent set of displayed plan amounts, so a comparison should preserve each offer’s unresolved terms. A selected arrangement should also explain whether a medicine change alters the charge and which professional addresses that question. The estimated price is a purchase fact; it is not evidence that the formulation or clinical purpose has already been agreed.
An included follow-up is not a finding about bleeding
Access to follow-up in Premium does not establish what a clinician would conclude about a new symptom or whether further in-person assessment would be needed. NHS guidance says postmenopausal bleeding should be checked even when it occurs once in a small amount. A service’s broad protection claim must not become a reason to dismiss it. The unexpected bleeding guide separates professional evaluation from subscription support. Hone’s public pages do not supply an individual investigation plan or prove that a membership message will receive an urgent clinical response. Those arrangements need confirmation with the service rather than inference from included consultations.
A useful review point revisits the original explanation
The menopause offer can support a discussion of symptoms and treatment options, but its advertised benefits are not a personal outcome guarantee. A later review should be understandable in relation to the reason a medicine was proposed, not merely whether another shipment was paid for. The unresolved questions include exact formulation, who supervises the plan, and how changes in history or symptoms are communicated. Our care comparison distinguishes delivery models without assigning a clinical winner. For Hone, the most important reading distinction is between a published compounded capsule option and the much more specific evidence and explanation needed for its use in an individual plan.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Hone Health: Menopause treatmentProvider menopause service, treatment goals and promotional timeline; not an individual outcome prediction · Checked 2026-09-29
- Hone Health: Progesterone Capsule for Women, Risks and BenefitsProvider capsule benefit claims, including an unqualified cancer-prevention statement; reviewed as marketing and limited with exact FDA label context · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- British Menopause Society: Induced menopause in women with endometriosis, February 2026UK professional clinical tool, February 2026; post-hysterectomy exceptions depend on residual disease and individual risks, with limited high-quality evidence and case-by-case decisions · Checked 2026-09-29
- NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29